Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) Shares Shorted: Short Interest Down 87.3% in September

Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) saw a large decrease in short interest in September. As of September 30th, there was short interest totaling 56,158 shares, a decrease of 87.3% from the September 15th total of 440,994 shares. Approximately 6.0% of the company’s stock are sold short. Based on an average daily trading volume, of 119,021 shares, the days-to-cover ratio is currently 0.5 days.

Matinas Biopharma Stock Performance

Shares of NYSEAMERICAN:MTNB traded up $0.04 during trading on Friday, hitting $2.87. The company’s stock had a trading volume of 35,267 shares, compared to its average volume of 142,341. The business has a 50 day moving average price of $3.03 and a two-hundred day moving average price of $6.76. The company has a market capitalization of $2.81 million, a PE ratio of -0.16 and a beta of 2.08. Matinas Biopharma has a fifty-two week low of $2.26 and a fifty-two week high of $28.95.

Matinas Biopharma (NYSEAMERICAN:MTNB) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($3.15) earnings per share (EPS) for the quarter.

Matinas Biopharma Company Profile

Matinas BioPharma, Inc is a clinical-stage biotechnology company developing medicines based on its proprietary lipid nanocrystal (LNC) delivery technology. The platform is designed to improve the oral delivery of active pharmaceutical ingredients that may otherwise have limited absorption or require intravenous administration.

The company’s lead program, MAT2203, is an oral formulation of amphotericin B, an antifungal medicine traditionally administered intravenously. Matinas has studied MAT2203 for serious systemic fungal infections, including cryptococcal meningitis, and has evaluated its potential to provide an orally administered alternative with fewer administration-related burdens.